{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:06:56Z","timestamp":1659096416586},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,7,1]]},"DOI":"10.2169\/internalmedicine.9433-22","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T22:10:20Z","timestamp":1650665420000},"page":"2073-2076","source":"Crossref","is-referenced-by-count":1,"title":["Successful Treatment of SARS-CoV-2 Vaccination-related Activation of Rheumatoid Arthritis with Positive Findings for Epstein-Barr Virus"],"prefix":"10.2169","volume":"61","author":[{"given":"Hideki","family":"Nakamura","sequence":"first","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Nagasawa","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadateru","family":"Takayama","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol 16: 207-228, 2020.","DOI":"10.1080\/1744666X.2019.1705785"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Patel V, Pulungan Z, Shah A, et al. Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs. J Med Econ 24: 299-307, 2021.","DOI":"10.1080\/13696998.2021.1881525"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Winthrop KL, Tanaka Y, Lee EB, et al. Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review. Clin Exp Rheumatol 40: 162-172, 2022.","DOI":"10.55563\/clinexprheumatol\/cpu6r9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Aberumand B, Dyck BA, Towheed T. Identifying perceptions and barriers regarding vaccination in patients with rheumatoid arthritis: a Canadian perspective. Int J Rheum Dis 23: 1526-1533, 2020.","DOI":"10.1111\/1756-185X.13971"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Stevens E, Weinblatt ME, Massarotti E, et al. Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center's experience with 400 patients. ACR Open Rheumatol 2: 357-361, 2020.","DOI":"10.1002\/acr2.11150"},{"key":"6","doi-asserted-by":"crossref","first-page":"e001464","DOI":"10.1136\/rmdopen-2020-001464","volume":"7","author":"R Hasseli","year":"2021","unstructured":"6. Hasseli R, Mueller-Ladner U, Hoyer BF, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 7: e001464, 2021.","journal-title":"RMD Open","ISSN":"http:\/\/id.crossref.org\/issn\/2056-5933","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79: 859-866, 2020.","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wilting FNH, Kotsopoulos AMM, Platteel ACM, van Oers JAH. Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia. Cureus 13: e17637, 2021.","DOI":"10.7759\/cureus.17637"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chevassut T, Hunt BJ, Pavord S. VITT, COVID-19 and the Expert Haematology Panel: the story of how the UK responded to emerging cases of vaccine-induced immune thrombocytopenia and thrombosis during the vaccination programme. Clin Med (Lond) 21: e600-e602, 2021.","DOI":"10.7861\/clinmed.2021-0488"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Levin D, Shimon G, Fadlon-Derai M, et al. Myocarditis following COVID-19 vaccination - a case series. Vaccine 39: 6195-6200, 2021.","DOI":"10.1016\/j.vaccine.2021.09.004"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. vanderLinden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology\/European League Against Rheumatism criteria. Arthritis Rheum 63: 37-42, 2011.","DOI":"10.1002\/art.30100"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Esquivel-Valerio JA, Skinner-Taylor CM, Moreno-Arquieta IA, et al. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study. Rheumatol Int 41: 2105-2108, 2021.","DOI":"10.1007\/s00296-021-05017-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yamamoto S, Nishimura K, Yo K, et al. Flare-up of adult-onset Still's disease after receiving a second dose of BNT162b2 COVID-19 mRNA vaccine. Clin Exp Rheumatol 39: 139-140, 2021.","DOI":"10.55563\/clinexprheumatol\/tvlpnc"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Baimukhamedov C, Makhmudov S, Botabekova A. Seropositive rheumatoid arthritis after vaccination against SARS-CoV-2 infection. Int J Rheum Dis 24: 1440-1441, 2021.","DOI":"10.1111\/1756-185X.14220"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Li P, Zhang X, Cao W, et al. RIG-I is responsible for activation of type I interferon pathway in Seneca Valley virus-infected porcine cells to suppress viral replication. Virol J 15: 162, 2018.","DOI":"10.1186\/s12985-018-1080-x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol 21: 195-197, 2021.","DOI":"10.1038\/s41577-021-00526-x"},{"key":"17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/pathogens10060763","volume":"10","author":"JE Gold","year":"2021","unstructured":"17. Gold JE, Okyay RA, Licht WE, et al. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens 10: 763, 2021.","journal-title":"Pathogens","ISSN":"http:\/\/id.crossref.org\/issn\/2076-0817","issn-type":"print"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Conaghan PG, Peterfy C, Olech E, et al. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Ann Rheum Dis 73: 810-816, 2014.","DOI":"10.1136\/annrheumdis-2013-204762"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kato A, Matsuo S, Takai H, Uchiyama Y, Mihara M, Suzuki M. Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp Mol Pathol 84: 262-270, 2008.","DOI":"10.1016\/j.yexmp.2008.03.003"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yamakawa N, Fujimoto M, Kawabata D, et al. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol 41: 293-299, 2014.","DOI":"10.3899\/jrheum.130270"},{"key":"21","unstructured":"21. Kitamura N, Sugiyama K, Nagasawa Y, et al. Involvement of Epstein-Barr virus in the development and spontaneous regression of methotrexate-associated lymphoproliferative disorder in patients with rheumatoid arthritis. Clin Exp Rheumatol. Forthcoming."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Fukui S, Nakamura H, Takahashi Y, et al. Tumor necrosis factor alpha inhibitors have no effect on a human T-lymphotropic virus type-I (HTLV-I)-infected cell line from patients with HTLV-I-associated myelopathy. BMC Immunol 18: 7, 2017.","DOI":"10.1186\/s12865-017-0191-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Endo Y, Fukui S, Koga T, et al. Tocilizumab has no direct effect on cell lines infected with human T-cell leukemia virus type 1. J Int Med Res 49: 3000605211002083, 2021.","DOI":"10.1177\/03000605211002083"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Biehl A, Harinstein L, Brinker A, et al. A case series analysis of serious exacerbations of viral hepatitis and non-viral hepatic injuries in tocilizumab-treated patients. Liver Int 41: 515-528, 2021.","DOI":"10.1111\/liv.14766"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/13\/61_9433-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T04:26:27Z","timestamp":1656735987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/13\/61_9433-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":24,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9433-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"article-number":"9433-22"}}